Outlook Therapeutics, Inc. (OTLK) stock
OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
$0.41+0.05 (+13.12%)
Close on Nov 18, 2026Market cap $99.30MP/E –Yield –
Outlook Therapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Outlook Therapeutics's pe ratio was 3.1× on Jul 31, 2025.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2025 | Jul 31, 2025 | 3.1× | – |
See a number that looks wrong?